Use of the self-controlled case series method in drug safety assessment

Expert Opinion on Drug Safety

Volumn 10, Issue 3, 2011, Pages 337-340

  Grosso, Anthony ^a,b   Douglas, Ian ^c   MacAllister, Raymond ^b   Petersen, Irene ^b   Smeeth, Liam ^c   Hingorani, Aroon D ^b  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; CIPROFLOXACIN;

ARTICLE; CASE STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; PRESCRIPTION; RISK FACTOR; TENDON RUPTURE;

CASE-CONTROL STUDIES; DRUG TOXICITY; PHARMACOEPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 79955426049     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.2011.562187     Document Type: Article

References (13)

1. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009;32(1):19-31
2. Farrington P, Pugh S, Colville A, et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995;345(8949):567-9
3. Whitaker HJ, Hocine MN, Farrington CP. The methodology of self-controlled case series studies. Stat Methods Med Res 2009;18(1):7-26
4. Grosso A, Douglas I, Hingorani AD, et al. Inhaled tiotropium bromide and risk of stroke. Br J Clin Pharmacol 2009;68(5):731-6
5. Grosso A, Douglas I, Hingorani A, et al. Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis. PLoS One 2009;4(3):e4720
6. Grosso A, Douglas I, Hingorani A, et al. Post-marketing assessment of the safety of strontium ranelate; a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008;66(5):689-94
7. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996;143(11):1165-73 (Pubitemid 26158114)
8. Whitaker H, Farrington CP, Spiessens B, Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006;25(10):1768-97
9. Henriksson M, Palmer S, Chen R, et al. Assessing the cost effectiveness of using prognostic biomarkers with decision models: case study in prioritising patients waiting for coronary artery surgery. BMJ 2010;340:b5606
10. Avorn J. In defense of pharmacoepidemiology - embracing the yin and yang of drug research. N Engl J Med 2007;357(22):2219-21 (Pubitemid 350190751)
11. Kazi D. Rosiglitazone and implications for pharmacovigilance. BMJ 2007;334(7606):1233-4 (Pubitemid 46975413)
12. Almenoff JS, Pattishall EN, Gibbs TG, et al. Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther 2007;82(2):157-66 (Pubitemid 47078877)
13. Clarke A, Deeks JJ, Shakir SA. An assessment of the publicly disseminated evidence of safety used in decisions to withdraw medicinal products from the UK and US markets. Drug Saf 2006;29(2):175-81 (Pubitemid 43213891)